Study Of AG-013736 In Patients With 131I-Refractory Thyroid Cancer

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

52 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-12-31

Study Completion Date

2012-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary purpose is to determine how effective AG-013736 is in shrinking thyroid cancer that is resistant to radioactive iodine

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of the Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Thyroid Cancer

NCT00094055

Thyroid Neoplasms

COMPLETED PHASE2

Treatment for Patients With Metastatic Thyroid Cancer

NCT00176748

Thyroid Cancer

COMPLETED PHASE2

A Study of AL2846 Capsule Versus Placebo in the Treatment of Advanced Radioiodine-Refractory Differentiated Thyroid Carcinoma

NCT06860971

Thyroid Cancer

RECRUITING PHASE3

A Study to Collect Information About the Use of Redifferentiating Medications as a Standard Treatment for Thyroid Cancer

NCT05733013

Thyroid Cancer Thyroid Refractory Thyroid Cancer

RECRUITING

Iodine I 131 and Pazopanib Hydrochloride in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer Previously Treated With Iodine I 131 That Cannot Be Removed By Surgery

NCT01413113

Recurrent Thyroid Cancer Stage IVA Follicular Thyroid Cancer Stage IVA Papillary Thyroid Cancer +4 more

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Additional study details: assess safety and efficacy

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Thyroid Neoplasms

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

A

Group Type EXPERIMENTAL

AG-013736

Intervention Type DRUG

AG-013736, tablets 5 mg BID , treatment will continue until tumor progression or toxicity

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

AG-013736

AG-013736, tablets 5 mg BID , treatment will continue until tumor progression or toxicity

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Radioiodine-refractory metastatic or unresectable locally-advanced thyroid cancer
* At least 1 measurable target lesion, as defined by RECIST

Exclusion Criteria

* Thyroid lymphoma
* Previous treatment with anti-angiogenesis agents
* No myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack, deep vein thrombosis or pulmonary embolism within 12 months prior.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No